KR950700333A - 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes) - Google Patents

개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)

Info

Publication number
KR950700333A
KR950700333A KR1019940702747A KR19940702747A KR950700333A KR 950700333 A KR950700333 A KR 950700333A KR 1019940702747 A KR1019940702747 A KR 1019940702747A KR 19940702747 A KR19940702747 A KR 19940702747A KR 950700333 A KR950700333 A KR 950700333A
Authority
KR
South Korea
Prior art keywords
alpha interferon
pct
peripheral blood
human peripheral
blood leukocytes
Prior art date
Application number
KR1019940702747A
Other languages
English (en)
Other versions
KR100223255B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR950700333A publication Critical patent/KR950700333A/ko
Application granted granted Critical
Publication of KR100223255B1 publication Critical patent/KR100223255B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1019940702747A 1992-02-10 1993-02-09 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법 KR100223255B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83503092A 1992-02-10 1992-02-10
US7835030 1992-02-10
PCT/US1993/001135 WO1993016107A1 (en) 1992-02-10 1993-02-09 Improved alpha interferon composition and method for its production from human peripheral blood leukocytes

Publications (2)

Publication Number Publication Date
KR950700333A true KR950700333A (ko) 1995-01-16
KR100223255B1 KR100223255B1 (ko) 1999-10-15

Family

ID=25268401

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702747A KR100223255B1 (ko) 1992-02-10 1993-02-09 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법

Country Status (11)

Country Link
US (1) US5503828A (ko)
EP (1) EP0625991B1 (ko)
JP (1) JPH07503851A (ko)
KR (1) KR100223255B1 (ko)
AT (1) ATE179330T1 (ko)
AU (1) AU674306B2 (ko)
CA (1) CA2129533A1 (ko)
DE (1) DE69324671D1 (ko)
PL (1) PL176408B1 (ko)
RU (1) RU2129437C1 (ko)
WO (1) WO1993016107A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101293990B1 (ko) * 2012-02-02 2013-08-07 희성촉매 주식회사 촉매담체 재생방법

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
EP0625991B1 (en) * 1992-02-10 1999-04-28 Interferon Sciences, Inc. Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
DE69528751T2 (de) * 1994-03-07 2003-07-10 Imperial College Verwendung von Interferon-alpha 8 subtype zur Herstellung von Medikamenten zur Behandlung von Viralinfektionen der Leber
US7294332B2 (en) * 1995-10-04 2007-11-13 Schering Corporation Combination therapy (temozolomide and α-IFN) for advanced cancer
US5972331A (en) * 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US5989441A (en) 1997-12-22 1999-11-23 Interferon Science, Inc. Recovery of functional human leukocytes from recycled filters
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6824768B2 (en) 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
WO2000039280A2 (en) * 1998-12-31 2000-07-06 Viragen, Inc. Leukocyte-derived interferon preparations
US6350589B1 (en) * 1998-12-31 2002-02-26 Viragen, Inc. Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
US6433144B1 (en) * 1999-01-12 2002-08-13 Viragen, Inc. Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
EP1337149A4 (en) 2000-10-27 2005-10-12 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS
JP2002201141A (ja) 2000-10-27 2002-07-16 Hayashibara Biochem Lab Inc 蛋白質合成抑制遺伝子の発現増強剤
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
WO2002087606A2 (en) * 2000-12-20 2002-11-07 Sri International Modulators of the hypocretin system and methods of screening therefor
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
PL371683A1 (en) * 2001-10-05 2005-06-27 Intermune, Inc. Methods of treating liver fibrosis and hepatitis c virus infection
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections
JP4866612B2 (ja) * 2003-11-12 2012-02-01 株式会社林原生物化学研究所 生理活性複合体
US20060159658A1 (en) * 2005-01-19 2006-07-20 Avigenics, Inc. Methods of treating disease with glycosylated interferon
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
JP5837730B2 (ja) * 2005-02-10 2015-12-24 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗インターフェロンアルファモノクローナル抗体及び使用方法
CU23432B6 (es) 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
US20070196333A1 (en) * 2006-02-23 2007-08-23 Fu-Yung Lin Composition comprising mixtures of IFN-alpha subtypes
CU23612A1 (es) * 2006-09-29 2010-12-08 Centro Inmunologia Molecular Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico
DK2234642T3 (en) 2007-11-28 2018-01-08 Irx Therapeutics Inc PROCEDURE FOR INCREASING AN IMMUNOLOGICAL EFFECT
DK2429585T3 (en) 2009-05-15 2018-07-30 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY
WO2011072006A1 (en) 2009-12-08 2011-06-16 Irx Therapeutics, Inc. Method of reversing immune suppression of langerhans cells
EP2753348B1 (en) * 2011-09-05 2019-12-11 Hanmi Science Co., Ltd. Pharmaceutical compositions comprising an interferon alpha conjugate and gemcitabine for the treatment of cancer
RU2672861C2 (ru) * 2014-10-31 2018-11-20 Общество с ограниченной ответственностью "Эксифарм" (ООО "Эксифарм") Композиция на основе интерферона I или III типа и гамма-D-глутаминил-L-триптофана для профилактики и лечения инфекционных заболеваний и иммунодефицитных состояний (варианты)
SG11202011815SA (en) * 2018-06-01 2020-12-30 Sanofi Sa Combination therapy for treating hepatitis b virus infection
CN113797317B (zh) * 2021-10-26 2024-01-09 科兴生物制药股份有限公司 一种组合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN150740B (ko) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4503035B1 (en) * 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
FI77877C (fi) * 1979-04-20 1989-05-10 Technobiotic Ltd Foerfarande foer framstaellning och rening av human le-formig interferonprotein.
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
WO1983000693A1 (en) * 1981-08-14 1983-03-03 Berg, Kurt, Frimann SUBJECTS RELATING TO HUMAN INTEFERON-'alpha' SUBTYPE PROTEINS AND CORRESPONDING ANTIBODIES
JPS60118196A (ja) * 1983-11-30 1985-06-25 Takeda Chem Ind Ltd インタ−フェロンの製造法
HU192254B (en) * 1983-12-13 1987-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing human leucocite and human gamma interferons in consecutive steps
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
JPS6156199A (ja) * 1984-08-27 1986-03-20 Shionogi & Co Ltd 新規ヒトインタ−フエロンα類
US4636383A (en) * 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
DE3508025A1 (de) * 1985-03-07 1986-09-11 Bayer Ag, 5090 Leverkusen Substituierte o-sulfonyl-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
EP0625991B1 (en) * 1992-02-10 1999-04-28 Interferon Sciences, Inc. Improved alpha interferon composition and method for its production from human peripheral blood leukocytes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101293990B1 (ko) * 2012-02-02 2013-08-07 희성촉매 주식회사 촉매담체 재생방법

Also Published As

Publication number Publication date
US5503828A (en) 1996-04-02
JPH07503851A (ja) 1995-04-27
WO1993016107A1 (en) 1993-08-19
ATE179330T1 (de) 1999-05-15
EP0625991B1 (en) 1999-04-28
KR100223255B1 (ko) 1999-10-15
AU3660093A (en) 1993-09-03
PL176408B1 (pl) 1999-05-31
EP0625991A4 (en) 1995-03-29
AU674306B2 (en) 1996-12-19
EP0625991A1 (en) 1994-11-30
RU2129437C1 (ru) 1999-04-27
DE69324671D1 (de) 1999-06-02
CA2129533A1 (en) 1993-08-19

Similar Documents

Publication Publication Date Title
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
MX9702932A (es) L-ribofuranosilnucleosidos.
EP0177910A3 (de) Verwendung von Interferon-gamma (IFN-gamma) enthaltenden Präparationen zur systemischen Behandlung von verschiedenen Erkrankungen des Menschen in niedriger Dosierung
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
RU94038043A (ru) Применение замещенных производных аденина для лечения множественного склероза
ATE152172T1 (de) Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
EP0151989A3 (en) Means for the treatment of cardiac diseases
DE59507920D1 (de) NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
ES2125976T3 (es) Otros derivados de indol con accion antiviral.
ATE163196T1 (de) Menschliche il-4 mutantenproteine
MX9702926A (es) L-eritrosilnucleosidos.
EP0553294A4 (en) Methods and compositions for the treatment of cell proliferation disorders
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
ZA923935B (en) New 2-amino-5-cyano-1,4-dihydropyridines,processes for their preparation and their use in medicaments
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
IL88726A0 (en) Dihydrothienobenzodiazepinone derivatives,pharmaceutical compositions containing the same and processes for the preparation thereof
HU9202026D0 (en) Method and medical preparative for treatment of thrombocytopenie
MX9702927A (es) L-piranosilnucleosidos.
MY111746A (en) Therapeutic nucleosides.
DE68924316T2 (de) Menschliches Gamma-Interferon, Verfahren zu seiner Herstellung und seine Verwendung.
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
IT9021051A0 (it) "procedimento di estrzione e purificazione del gamma interferone umano ricombite"
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee